The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-bl...

por Ritchlin, Christopher T., Coates, Laura C., Mease, Philip J., van der Heijde, Désirée, Song, Jiao, Jiang, Yusang, Shawi, May, Kollmeier, Alexa P., Rahman, Proton
Publicado 2023

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis...

por Ritchlin, Christopher T., Deodhar, Atul, Boehncke, Wolf‐Henning, Soriano, Enrique R., Kollmeier, Alexa P., Xu, Xie L., Zazzetti, Federico, Shawi, May, Jiang, Yusang, Sheng, Shihong, Helliwell, Philip S.
Publicado 2023

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, plac...

por Gottlieb, Alice B, McInnes, Iain B, Rahman, Proton, Kollmeier, Alexa P, Xu, Xie L, Jiang, Yusang, Sheng, Shihong, Shawi, May, Chakravarty, Soumya D, Lavie, Frederic, Mease, Philip J
Publicado 2023

Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phas...

por Orbai, Ana-Maria, Coates, Laura C., Deodhar, Atul, Helliwell, Philip S., Ritchlin, Christopher T., Leibowitz, Evan, Kollmeier, Alexa P., Hsia, Elizabeth C., Xu, Xie L., Sheng, Shihong, Jiang, Yusang, Liu, Yan, Han, Chenglong
Publicado 2022

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Bl...

por McInnes, Iain B., Rahman, Proton, Gottlieb, Alice B., Hsia, Elizabeth C., Kollmeier, Alexa P., Xu, Xie L., Jiang, Yusang, Sheng, Shihong, Shawi, May, Chakravarty, Soumya D., van der Heijde, Désirée, Mease, Philip J.
Publicado 2022

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 5...

por Ritchlin, Christopher T, Mease, Philip J, Boehncke, Wolf-Henning, Tesser, John, Schiopu, Elena, Chakravarty, Soumya D, Kollmeier, Alexa P, Xu, Xie L, Shawi, May, Jiang, Yusang, Sheng, Shihong, Wang, Yanli, Xu, Stephen, Merola, Joseph F, McInnes, Iain B, Deodhar, Atul
Publicado 2022

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis

por McInnes, Iain B., Rahman, Proton, Gottlieb, Alice B., Hsia, Elizabeth C., Kollmeier, Alexa P., Chakravarty, Soumya D., Xu, Xie L., Subramanian, Ramanand A., Agarwal, Prasheen, Sheng, Shihong, Jiang, Yusang, Zhou, Bei, Zhuang, Yanli, van der Heijde, Désirée, Mease, Philip J.
Publicado 2021

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study...

por Ritchlin, Christopher T, Helliwell, Philip S, Boehncke, Wolf-Henning, Soriano, Enrique R, Hsia, Elizabeth C, Kollmeier, Alexa P, Chakravarty, Soumya D, Zazzetti, Federico, Subramanian, Ramanand A, Xu, Xie L, Zuraw, Qing C, Sheng, Shihong, Jiang, Yusang, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, Shawi, May, Karyekar, Chetan S, Deodhar, Atul
Publicado 2021